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Abstract
Glioblastoma multiforme (GBM) is the most common type of malignant brain tumors in adults and has a dismal prognosis.
The highly aggressive invasion of malignant cells into the normal brain parenchyma renders complete surgical resection of
GBM tumors impossible, increases resistance to therapeutic treatment, and leads to near-universal tumor recurrence. We
have previously demonstrated that TROY (TNFRSF19) plays an important role in glioblastoma cell invasion and therapeutic
resistance. However, the potential downstream effectors of TROY signaling have not been fully characterized. Here, we
identified PDZ-RhoGEF as a binding partner for TROY that potentiated TROY-induced nuclear factor kappa B activation
which is necessary for both cell invasion and survival. In addition, PDZ-RhoGEF also interacts with Pyk2, indicating that
PDZ-RhoGEF is a component of a signalsome that includes TROY and Pyk2. PDZ-RhoGEF is overexpressed in
glioblastoma tumors and stimulates glioma cell invasion via Rho activation. Increased PDZ-RhoGEF expression enhanced
TROY-induced glioma cell migration. Conversely, silencing PDZ-RhoGEF expression inhibited TROY-induced glioma cell
migration, increased sensitivity to temozolomide treatment, and extended survival of orthotopic xenograft mice.
Furthermore, depletion of RhoC or RhoA inhibited TROY- and PDZ-RhoGEF–induced cell migration. Mechanistically,
increased TROY expression stimulated Rho activation, and depletion of PDZ-RhoGEF expression reduced this activation.
Taken together, these data suggest that PDZ-RhoGEF plays an important role in TROY signaling and provides insights into
a potential node of vulnerability to limit GBM cell invasion and decrease therapeutic resistance.
Neoplasia (2018) 20, 1045–1058

Introduction
Glioblastoma multiforme (GBM), a grade IV astrocytoma, is the most
common primary central nervous system tumor in human adults and
remains largely incurable with a median life expectancy of approximately
15 months [1,2]. Despite advances in therapeutic treatments of GBM,
including surgical resection, chemotherapy, and radiation therapy, overall
patient survival has not shown significant improvement over the past decade
[1]. A hallmark of malignant gliomas is the extensive invasion of tumor cells
into the normal brain parenchyma [3], which implies that even extensive
resection of the primary tumor mass is not curative. Moreover, the invading
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cells are highly resistant to current therapeutic modalities, consequently
leading to tumor recurrence [4]. However, the molecular mechanisms
underlying glioma cell invasion have remained elusive. Thus, a deeper
understanding of the signaling pathways that drive glioma cell invasion as
well as the identification and specific targeting of the crucial signaling
effectors is needed to ultimately improve the treatments for this disease.
Among the important mediators of glioblastoma cell invasion is
TROY, an orphan member of the tumor necrosis factor receptor
superfamily, which is widely expressed during embryonic development
but whose postnatal expression is tightly regulated [5–8]. Increased
expression of TROY has been implicated in several invasive cancers,
including melanoma, nasopharyngeal carcinoma, lung cancer, colorectal
cancer, and GBM [9–14]. We have previously shown that expression of
TROY protein is low in non-neoplastic brain tissue but increases with
glial tumor grade and inversely correlates with patient survival [13]. We
also noted that TROY mRNA expression was elevated in invasive glioma
cells relative to cells in the matched tumor core [14]. Increased expression
of TROY stimulated glioma cell invasion in vitro and invasion ex vivo in
brain slices, and induced astrocyte migration in situ. TROY-stimulated
migration correlated with increased glioma cell resistance to temozolomide (TMZ) or radiation in vitro via activation of Akt and the nuclear
factor kappa B (NF-κB) [14]. Conversely, knockdown of TROY
expression inhibited glioma cell migration and increased sensitivity to
TMZ [14]. Furthermore, knockdown of TROY expression alone
significantly increased survival in an intracranial xenograft model [14].
Recently, we found that TROY forms a novel complex with epidermal
growth factor receptor and that TROY was capable of modulating
epidermal growth factor receptor signaling in GBM [15]. However, the
signaling pathways and specific downstream effectors involved in
TROY-stimulated cell migration and invasion remain largely undefined.
The Rho GTPases, a subgroup of the Ras superfamily, play important
roles in a wide spectrum of cellular functions such as actin cytoskeletal
reorganization, cell cycle progression, and vesicle trafficking [16]. They
act as molecular switches by cycling between an active (GTP-bound) and
an inactive (GDP-bound) conformational state. The switch is primarily
regulated by guanine nucleotide exchange factors (GEFs), catalyzing the
exchange of GDP for GTP, and GTPase-activating proteins, promoting
the hydrolysis of GTP bound to Rho GTPases to deactivate the Rho
GTPases [17]. Emerging evidence has demonstrated that Rho GEFs link
many receptor tyrosine kinases to Rho GTPase activation [18,19]. Given
their central role as regulators of the cytoskeleton, cell cycle, cellular
polarity, cell adhesion, and cell migration, RhoGEFs have been
implicated in cancer cell invasion and tumor progression [20].
In this study, we sought to identify downstream effectors involved
in TROY-induced glioma cell migration and invasion. We identified
PDZ-RhoGEF (ARHGEF11) as a component of a signalsome that
includes TROY and the non–receptor tyrosine kinase Pyk2 [13].
PDZ-RhoGEF expression is significantly increased in GBM tumors and
stimulates the migration of TROY-expressing GBM cells. PDZ-RhoGEF
can exchange for both RhoA and RhoC linking TROY signaling to Rho
activation. The current results substantiate a role for PDZ-RhoGEF as an
effector of TROY signaling and suggest that PDZ-RhoGEF may
represent a novel target to inhibit GBM cell invasion.
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293 cells, and T98G cells transduced with a shRNA targeting TROY
[14] as well as the 293/NF-κB-luc reporter cell line [15] were maintained
in Dulbecco's modified Eagle medium (DMEM) (Invitrogen) supplemented with 10% heat-inactivated FBS (Invitrogen), 1% nonessential
amino acids, 2 mmol/l glutamine, 100 U/ml penicillin, and 100 μg/ml
streptomycin at 37°C with 5% CO2. When indicated, cells were serum
starved by replacing the culture media with DMEM supplemented with
0.1% bovine serum albumin (BSA). GBM43 and GBM10 are primary
GBM patient-derived xenografts (PDX) obtained from the Mayo Clinic
Brain SPORE [21]. These PDX were established directly from patient
surgical samples and maintained as subcutaneous flank xenografts
through serial passaging in immune-deficient mice. Extensive phenotypic and genotypic characterizations of these models as well as their
growth properties in flank and brain and the response of orthotopic
tumors to various therapies are available at https://www.mayo.edu/
research/labs/translational-neuro-oncology/mayo-clinic-brain-tumorpatient-derived-xenograft-national-resource. Fresh flank tumors were
resected, processed to single cell suspension by mechanical dissociation,
and maintained in neurosphere media (DMEM/F12 containing 2%
B-27 supplement, 20 ng/ml bFGF, and 20 ng/ml EGF).

Antibodies, Expression Constructs, and Reagents
A polyclonal PDZ-RhoGEF antibody was purchased from Novus
Biologicals (Littleton, CO). Antibodies to HA-epitope tag, α-tubulin,
β-tubulin, and RhoC were purchased from Cell Signaling Technologies
(Beverly, MA). A rabbit polyclonal antibody to TROY was produced by
Cocalico Biologicals (Reamstown, PA) using a peptide mapping to the
TROY amino terminus conjugated to KLH. The anti-RhoA antibody
and the anti–PDZ-RhoGEF monoclonal antibody were obtained from
Santa Cruz biotechnology (Dallas, TX). The anti-Myc monoclonal
antibody (9E10), the anti-Rac1 monoclonal antibody, and the anti-Pyk2
polyclonal antibody were obtained from Millipore (Bedford, MA). The
anti-FLAG antibody was obtained from Sigma (St. Louis, MO). The
polyclonal anti-AU1 epitope antibody and the polyclonal anti-Myc
epitope antibody were obtained from Bethyl Laboratories (Montgomery,
TX). The anti-phosphotyrosine mAb pY20 was from BD Biosciences
(San Jose, CA). The β-actin monoclonal antibody was obtained from
ThermoFisher Scientific (San Jose, CA). Alexa Fluor 546–labeled goat
anti-rabbit antibody and Alexa Fluor 488–labeled goat anti-mouse
antibody were purchased from Invitrogen (Carlsbad, CA). The 3X HA
epitope-tagged wild-type (WT) TROY construct was constructed as
previously described [13]. The AU1 epitope-tagged TROY was
generated by replacing the 3X HA epitope with the AU1 epitope
(DTYRYI) by PCR. Generation of the FLAG-epitope tagged wild-type
Pyk2 and kinase-deficient Pyk2 K457A variant has been previously
described [22]. Plasmids encoding rat PDZ-RhoGEF and leukemia-associated Rho guanine nucleotide exchange factor (LARG) [23] were
generously provided by Zhekang Ying (University of Maryland School of
Medicine). To generate FLAG epitope-tagged wild-type PDZ-RhoGEF,
the coding sequence of PDZ-RhoGEF was cloned in-frame downstream
of a 3X FLAG epitope in pcDNA3. Recombinant E1-deleted adenovirus
for this construct was prepared using the Ad-Easy system as previously
described [24]. Collagen was obtained from Advanced Biomatrix
(San Diego, CA). EGF was obtained from Invitrogen (Carlsbad, CA).

Materials and Methods

Cell Culture

Generation of NF-κB Response Element–Driven Firefly Luciferase
Reporter Stable Cell Lines Overexpressing HA Tagged TROY

Authenticated human astrocytoma cell lines U87MG and T98G
(American Type Culture Collection), human kidney epithelial cell line

A cDNA fragment encoding WT TROY with a C-terminal 3X HA
epitope-tag was subcloned into the lentiviral transfer vector pCDH GFP
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(System Biosciences) as previously described [14]. The empty pCDH
lentiviral construct expressing only GFP was used as control.
Recombinant lentiviruses encoding TROY-HA were produced by
transient transfection of 293T packing cells with pCDH construct
encoding HA tagged TROY and the pPACKH1 plasmid packing mix
(System Biosciences). 293/NF-κB-luc cells, a NF-κB response element–
driven firefly luciferase reporter cell line [15], and T98G/NF-κB-luc cells
were transduced with the recombinant TROY-HA lentiviruses and
selected by mass sorting the GFP-positive cells on a FACS Aria cell sorter
(BD Biosciences) to generate the reporter cell lines designated 293/
NF-κB-luc/TROY-HA and T98G/NF-κB-luc/TROY-HA, respectively.

Immunoblotting and Immunoprecipitation
Immunoblotting of cell lysates and protein determination were
performed as described [15,25]. Briefly, cells were washed with ice-cold
PBS once and lysed on ice in the presence of protease and phosphatase
inhibitors, lysates were clarified by centrifugation, and protein
concentrations were measured using bicinchoninic acid assay (Pierce)
with bovine serum albumin as a standard. For immunoblotting, equal
amounts of cell lysates were resolved by SDS-PAGE, transferred to
nitrocellulose, and incubated with the appropriate primary antibody.
Protein detections were performed using IRDye-conjugated secondary
antibodies with the Odyssey CLx Infrared Imaging System (LI-COR
Biosciences).
For immunoprecipitation experiments, cells were lysed 24 hours after
transfection with RIPA buffer (50 mM Tris, pH 8.0, 135 mM NaCl,
1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, and 5% glycerol)
containing protease and phosphatase inhibitors. Eight hundred
micrograms of cell lysates was precleared with protein G-agarose beads
(Millipore) for 1 hour at 4°C. Precleared lysates were incubated with the
appropriate antibodies at a dilution of 1:100 overnight at 4°C followed
by incubation with protein G-agarose beads for 1 hour. The immune
complexes were washed five times with ice-cold RIPA buffer, eluted with
2× SDS sample buffer, boiled in the presence of 2-mercaptoethanol
(Sigma), and resolved by SDS-PAGE. Immunoblotting of resolved
immunoprecipitates was performed as described above.

Immunofluorescence
T98G, GBM10, and GBM43 cells were plated onto four-chamber
glass slides. Twenty-four hours later, cells were fixed in 4%
formaldehyde, permeabilized with 0.1% Triton-X100, blocked in 5%
normal goat serum, and incubated with a 1:100 dilution of polyclonal
rabbit anti-TROY antibody and mouse anti–PDZ-RhoGEF antibody
at 4°C overnight. The following day, the samples were washed three
times in PBS and incubated with a 1:1000 dilution of Alexa Fluor 546–
labeled goat anti-rabbit antibody and Alexa Fluor 488–labeled goat
anti-mouse antibody in dark for 1 hour at room temperature. Slides
were mounted with ProLong Gold Antifade Reagent with DAPI (Cell
Signaling Technology). Images were collected using a Zeiss LSM 800
microscope equipped with a 63× objective, ZEN image analysis
software, and Adobe Photoshop CC 2015.

Glioblastoma Tissue Microarray and Immunohistochemistry
The preparation of the glioblastoma tissue microarray and immunohistochemistry protocols used to examine PDZ-RhoGEF expression in
glioblastoma tumor samples has been described previously [26]. A
standard histological scoring system of 0, negative; 1, weak; 2, moderate;
and 3, strong was used to grade the staining by individuals blinded to the
sample identity.
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Small Interfering RNA (siRNA) Transfection
siRNA oligonucleotides specific for GL2 luciferase were described
previously [27]. siRNA target sequences for PDZ-RhoGEF (PRG),
RhoA, and RhoC were as follows: PRG-1 (5′-ACCGUACAAACCAC
CAAAUCCUCUG-3′), PRG-2 (5′-GCGAUUCAAUCCUGAU
CAA-3′), RhoA-1 (5′-AUGGAAAGCAGGUAGAGUU-3′), RhoA-2
(5′-CCCAGAUACCGAUGUUAUACUGAUG-3′), RhoC-1 (5′-GAA
CUAUAUUGCGGACAUU-3′), and RhoC-2 (5′-GGACAUGGCGA
ACCGGAUC-3′). The negative control siRNA (Silencer Negative
Control #1 siRNA, AM4611) was obtained from Ambion (Austin, TX).
The cells were transfected with siRNA using Lipofectamine RNAiMax
(Invitrogen) according to the manufacture's protocols. Two or 3 days after
transfection, depletion of the respective proteins was confirmed by
immunoblotting using the indicated antibodies.

shRNA Transduction
Lentivirus constructs encoding a validated short hairpin RNA
(shRNA)-targeting human TROY (Clone ID: V2LHS 30848) or a
nonsilencing control shRNA (Catalog #RHS4348) were purchased from
Thermo Fisher Open Biosystems. Three different shRNAs targeting
PDZ-RhoGEF (Clone IDs: V3LHS 373445, V3LHS 373447, or
V2LHS 95367) were also purchased from Thermo Fisher Open
Biosystems. Preliminary experiments indicated V3LHS 373445
exhibited the greatest knockdown efficacy and was used in subsequent
studies. shRNA transduction was performed as previously described
[14]. Briefly, recombinant lentiviruses encoding shRNAs were produced
by transient transfection of 293T packaging cells with the shRNA
expression constructs and the Trans-Lentiviral packaging kit (Open
Biosystems). For lentiviral transduction, media from the packing cells
were harvested 48 hours after transfection; recombinant lentiviruses
were concentrated by polyethylene glycol precipitation and added to
GBM10 or GBM43 cells with 8 μg/ml polybrene for 6 hours at 37°C.
Positively transduced cells were enriched by mass sorting the
GFP-positive cells using a FACS Aria cell sorter (BD Biosciences).

Intracranial Xenograft Tumor Model
The orthotopic intracranial xenograft model was conducted under a
protocol approved by the Mayo Institutional Animal Care and Use
Committee. The procedure was performed as previously described [14].
Power analysis indicated that a sample size of 8 animals for each group
will have 80% power to detect a probability of 0.90 that the time until
onset of a moribund state in one group is less than the time until onset of
a moribund state in another group using a Wilcoxon (Mann-Whitney)
rank sum test with a .05 two-sided significance level. Female athymic
nude mice were randomized into groups of 10 that received either
GBM10 cells transduced with a nontargeting control shRNA or
GBM10 cells transduced with a shRNA-targeting PDZ-RhoGEF.
Extent of knockdown of PDZ-RhoGEF was examined by immunoblotting analysis of transduced cells 48 hours after injections. Cells
(5 × 10 5 cells) were injected into the right basal ganglia of
anesthetized mice with a stereotaxic frame. Mice were weighed daily
and monitored for the onset of neurologic symptoms and euthanized
when they reached a moribund condition.

Organotypic Brain Slice Invasion Assay
Preparation and culture of adult brain slice were performed as
described previously [28]. Briefly, GFP-labeled U87MG glioma cells
transfected with siRNA targeting PDZ-RhoGEF or a control siRNA
were placed onto the putamen of the brain slice. After 48 hours,
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glioma cell invasion into rat brain slices was quantified by confocal
microscopy, and the depth of invasion (z-axis stacks) was calculated as
described previously [22,28].

Transwell Migration Assays
Glioma cells were seeded in 100-mm–diameter dishes and incubated
overnight at 37°C. Subsequently, the culture media were replaced with
DMEM and 0.1% BSA for additional 16 hours at 37°C. Cells were
harvested, resuspended in DMEM and 0.1% BSA (1 × 10 5 cells/200 μl),
added in triplicate to collagen-coated Transwell chambers (8-μm pore size),

Neoplasia Vol. 20, No. 10, 2018

and allowed to migrate towards 10% serum. After incubation for 24 hours
at 37°C, cells on the upper surface of the membrane were scraped off.
Migrated cells on the lower surface of the membrane were fixed with 4%
paraformaldehyde and stained with ProLong Gold Antifade reagent with
DAPI (Invitrogen). Nuclei of migrated cells were counted in five
high-power fields with a 20× objective.

Cell Viability Assays
The CellTiter-Glo assay (Promega) was used to examine the cell
viability after TMZ treatment as previously described [29]. Briefly,
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GBM43 cells transduced with a shRNA-targeting TROY or GBM43
cells transduced with a nontargeting control shRNA were seeded in
96-well plates in DMEM with 10% FBS at a density of 3000 cells/well.
Increasing concentration of TMZ was added to the different wells with
six replicates under each condition and incubated for 72 hours at 37°C.
Subsequently, CellTiter-Glo reagent was added to each well, and
luminescence was measured using Cytation 5 Multi-Mode Reader
(BioTek). The data were normalized to control cells (TMZ 0 μM,
100% cell viability) and plotted as mean +/− SD.

Rho Activation Assay
GTP loading of Rho activity was measured using the Rho Activation
Assay Kit (Cytoskeleton) according to the manufacturer's instructions.
Briefly, glioma cells were plated in 100-mm dishes and incubated
overnight. Cells were 0.1% BSA serum starved for 16 hours, cell lysates
were harvested, and equal amounts of proteins were assessed for
Rho activation.

Luciferase Reporter Assays
Reporter cells were plated in complete DMEM in six-well plates.
The cells were transfected in triplicate with indicated plasmids using
Effectene (Qiagen). Cells were serum starved (0.1% BSA in DMEM)
for 16 hours and then lysed in Reporter Lysis Buffer (Promega).
Luciferase assays were performed using the luciferase reporter assay
system (Promega) according to the manufacturer's instructions.

Statistical Analysis
Statistical analyses were conducted by the two-sample t test using
GraphPad Prism 7.0 (GraphPad, Inc.). A P value less than .05 was
considered significant. Survival of mice with intracranial xenografts was
determined by Kaplan-Meier analysis using GraphPad Prism 7.0.
Differences between survival curves were compared with the log-rank
test. Statistical significance was set at criterion level P b .01.
Results

Identification of PDZ-RhoGEF as a Component of a Signalsome
That Includes TROY and Pyk2
To determine possible mechanisms through which TROY induces
GBM cell invasion, we performed immunoprecipitation of TROY
from T98G glioma cells overexpressing TROY and analyzed the
precipitates with MALDI-TOF and MS/MS to identify proteins that
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are capable of interacting with TROY and potentially mediating
TROY signaling [13]. Several proteins were identified in the TROY
immunoprecipitates, among which PDZ-RhoGEF was of particular
interest because it has previously been reported to be involved in cellular
motility [30,31]. To confirm the interaction between TROY and
PDZ-RhoGEF, 293 cells co-transfected with HA-tagged TROY and
Myc-tagged PDZ-RhoGEF were immunoprecipitated with an
anti-Myc antibody, and the precipitates were immunoblotted with
anti-HA and anti-Myc antibodies. Immunoblotting demonstrated that
HA-tagged TROY co-immunoprecipitated with Myc-tagged
PDZ-RhoGEF, substantiating an interaction between TROY and
PDZ-RhoGEF (Figure 1A). Endogenous PDZ-RhoGEF was found to
co-immunoprecipitate with endogenous TROY in T98G glioma cells
as well as primary GBM patient-derived xenografts GBM10 and
GBM43 cells (Figure 1, B-D). The expression pattern of endogenous
TROY and TROY interactants in the different cells lines is shown in
Supplementary Figure 1. To explore the specificity of the interaction
between TROY and PDZ-RhoGEF, we examined whether TROY could
interact with LARG, a closely related GEF belonging to the same
RhoGEF subfamily as PDZ-RhoGEF. 293 cells were co-transfected with
HA-tagged LARG and/or Myc-tagged TROY. Immunoprecipitation of
the transfected cell lysates with an anti-Myc antibody followed by
immunoblotting of the precipitates with the anti-HA antibody showed
that LARG was not present in the TROY-Myc immunoprecipitates,
suggesting a specific interaction of TROY with PDZ-RhoGEF (Figure
1E). To further confirm the interaction, we examined the colocalization of
TROY and PDZ-RhoGEF by immunofluorescence analysis. T98G,
GBM10, and GBM43 cells were stained with anti-TROY and anti–
PDZ-RhoGEF antibodies and examined by confocal microscopy (Figure
1F). Consistent with previous results [13], TROY staining was
predominately near the cell periphery and enriched in lamellipodia, and
the merged images indicated colocalization of TROY and
PDZ-RhoGEF.
In a previous study using MALDI-TOF and MS/MS analysis of
immunoprecipitates of TROY from T98G glioma cells, we identified
the non–receptor tyrosine kinase Pyk2 in the TROY immunoprecipitate
and verified their association by co-immunoprecipitation [13]. In
addition, we demonstrated that TROY-induced cell migration and
invasion were dependent upon Pyk2 expression and activity. Given that
both Pyk2 and PDZ-RhoGEF were found to associate with TROY, we
examined whether we could observe a signaling complex that includes

Figure 1. TROY associates with PDZ-RhoGEF (PRG). (A) 293 cells were co-transfected with HA-tagged TROY plasmid and Myc-tagged
PDZ-RhoGEF plasmid, and the lysates were immunoprecipitated with an anti-Myc antibody or mouse IgG. The immunoprecipitates were
analyzed for the presence of PDZ-RhoGEF by immunoblot analysis. The expression level of Myc-tagged PDZ-RhoGEF and HA-tagged TROY in the
cells is shown by immunoblotting of whole cell lysates (WCL). (B-D) The lysates of T98G, GBM10, and GBM43 cells were immunoprecipitated
with an anti-TROY antibody or rabbit IgG. The immunoprecipitates were analyzed for the presence of PDZ-RhoGEF by immunoblot analysis. The
expression level of PDZ-RhoGEF and TROY in the cells is shown by immunoblotting of WCL. (E) TROY does not co-immunoprecipitate with LARG
in 293 cells. 293 cells were transfected with HA-tagged LARG or Myc-tagged TROY, or co-transfected with HA-tagged LARG and Myc-tagged
TROY. Twenty-four hours after transfection, cells were lysed and immunoprecipitated with anti-Myc antibody. Immunoprecipitates or WCL were
immunoblotted with the indicated antibodies. (F) Colocalization of TROY and PDZ-RhoGEF in T98G, GBM10, and GBM43 cells. Cells were stained
and examined by confocal microscopy. TROY was visualized with Alexa Fluor 546–conjugated antibody, and PDZ-RhoGEF was visualized with
Alexa Fluor 488–conjugated antibody. The colocalization of TROY (red) with PDZ-RhoGEF (green) appears as a yellow color in the merged image.
Cells were counterstained with DAPI (blue) (bars = 10 μm). (G) 293 cells were co-transfected with AU1-tagged TROY, Myc-tagged PRG, and
HA-tagged Pyk2, and 24 hours later, cells were lysed and immunoprecipitated with goat anti-Myc or goat anti-AU1 antibodies or goat IgG.
Immunoprecipitates or WCL were immunoblotted (IB) with the indicated antibodies. (H) Left panel, 293 cells were transfected with HA-tagged
LARG and/or FLAG-tagged Pyk2. Twenty-four hours later, the cells were lysed and immunoprecipitated with anti-FLAG antibody or mouse IgG.
Immunoprecipitates or WCL were IB with anti-FLAG or anti-HA antibodies. Right panel, 293 cells were co-transfected with Myc-tagged PRG and
FLAG-tagged WT Pyk2 or kinase-deficient (KD) Pyk2 for 24 hours. Cells were lysed and immunoprecipitated with anti-Myc antibody.
Immunoprecipitates or WCL were IB with the indicated antibodies.
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TROY, Pyk2, and PDZ-RhoGEF. Cells were transfected with epitope
tagged variants of TROY, Pyk2, and PDZ-RhoGEF; cell lysates were
immunoprecipitated with antiepitope antibodies; and the precipitates
were immunoblotted with antibodies for each of the components
(Figure 1G). Both the anti-TROY and the anti–PDZ-RhoGEF
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immunoprecipitates contained TROY, PDZ-RhoGEF, and Pyk2,
indicating the presence of a TROY signalsome that includes Pyk2 and
PDZ-RhoGEF.
Previous studies have reported that tyrosine phosphorylation is among
several mechanisms described for the activation of RhoGEFs [17,18].

Figure 2. Depletion of PDZ-RhoGEF expression inhibits glioma cell migration and invasion and TROY-stimulated glioma cell migration.
(A) U87MG cells were transfected with two independent siRNAs targeting PDZ-RhoGEF (PRG-1, PRG-2) or with a control siRNA targeting firefly
luciferase (Luc). Cell lysates were analyzed for PDZ-RhoGEF by immunoblotting. Immunoblotting of β-tubulin protein was used as a loading
control. (B) Invasion of U87MG cells transfected with siRNAs targeting PDZ-RhoGEF (PRG-1, PRG-2) or luciferase (Luc). Forty-eight hours after cell
seeding onto the brain slice, glioma cell invasion into the brain slices was quantified using confocal microscopy. The data are depicted as the
mean values (+/− SEM) from three separate experiments. ***P b .001. (C) Migration of T98G cells and T98G cells overexpressing TROY (T98G/
TROY-HA) transfected with siRNAs targeting PDZ-RhoGEF (siPRG-1, siPRG-2) or a nonsilencing control (siCTRL). Data represent the mean values
(+/− SEM) (n = 3, **, P b .01; ***, P b .001). Cell lysates were analyzed by immunoblotting with indicated antibodies. Immunoblotting
of tubulin was used as a loading control. (D) Knockdown of PDZ-RhoGEF expression in patient xenograft GBM43 cells transduced with the
shRNA-targeting PDZ-RhoGEF (PRG) or the control (CTL) nontargeting shRNA. Cell lysates were analyzed by immunoblotting with indicated
antibodies. Immunoblotting of β-actin protein was used as a loading control. (E) Primary xenograft GBM43 cells transduced with a control
nonsilencing shRNA (NS Ctrl) or shRNA targeting PDZ-RhoGEF (PRG) were treated with the indicated concentration of TMZ. Cell viability was
assessed after 72 hours by CellTiter-Glo assay. Data are depicted as the mean values (+/− SD) of six replicates. ***P b .001.
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Notably, phosphorylation has been previously reported to regulate the
activity of PDZ-RhoGEF in 293 cells [32]. Therefore, we investigated
further the interaction between Pyk2 and PDZ-RhoGEF. Studies
examining the specificity of the interaction demonstrated that Pyk2
co-immunoprecipitated with PDZ-RhoGEF but failed to immunoprecipitate with the closely related RhoGEF LARG (Figure 1H) consistent
with the inability of TROY to associate with LARG. Moreover,
PDZ-RhoGEF present in the co-immunoprecipitate with wild-type
Pyk2 was phosphorylated but not in the co-immunoprecipitate with a
kinase inactive Pyk2 (Figure 1H). Together, these results suggest a
potential TROY signaling pathway that includes Pyk2 and
PDZ-RhoGEF.

Depletion of PDZ-RhoGEF Inhibits TROY-Induced Glioblastoma
Cell Invasion and Increases Sensitivity to TMZ
To examine the role of PDZ-RhoGEF in glioma cell invasion,
we used RNA interference to knock down the expression of
PDZ-RhoGEF and examined the effect on cell invasion using an
ex vivo rat brain slice model [22,28]. U87MG cells were transfected with
two independent siRNA oligonucleotides targeting PDZ-RhoGEF for
72 hours, and the cell lysates were subjected to immunoblotting with an
anti–PDZ-RhoGEF antibody. Immunoblotting analysis showed that
siRNA-induced knockdown of PDZ-RhoGEF expression in U87MG
with both siRNA oligonucleotides was N90% effective relative to
cells transfected with a control siRNA targeting firefly luciferase (luc)
(Figure 2A). U87MG cells transfected with siRNA targeting
PDZ-RhoGEF or the control siRNA (luc) were seeded onto the brain
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slice, and cell invasion into the brain slice was quantified after 48 hours
using confocal microscopy [28]. Knockdown of PDZ-RhoGEF in
U87MG cells resulted in a significant inhibition in the depth of invasion
relative to U87MG cells expressing the control siRNA, supporting a role
for PDZ-RhoGEF in glioma cell invasion signaling (P b .001; Figure
2B). To further determine the role of PDZ-RhoGEF in TROY-induced
glioma cell migration, we used RNA interference to knockdown the
expression of PDZ-RhoGEF in T98G cells and T98G cells overexpressing TROY (T98G/TROY-HA) and examined the migratory
behavior of these cells using Transwell migration assay. These cells were
transfected with two independent siRNAs targeting PDZ-RhoGEF
(siPRG-1, siPRG-2) or a nontargeting control siRNA (siCTRL) for
48 hours, serum starved overnight, and seeded on the top of transwell
chambers. Ten percent serum was added into the lower chamber as
chemoattractant. Cell migration into the lower chamber was quantified
after 24 hours. Knockdown of PDZ-RhoGEF was confirmed by
immunoblotting analysis (Figure 2C). Migration assays showed that
increased expression of TROY increased cell migration consistent with
previous results [13]. Knockdown of PDZ-RhoGEF expression
inhibited the migration of T98G cells and also significantly inhibited
the TROY-stimulated increased cell migration (Figure 2C), supporting a
role of PDZ-RhoGEF in TROY-induced glioma cell migration.
Since elevated TROY expression stimulates cell migration/invasion
and increases therapeutic resistance to TMZ [13,14], we hypothesized
that if PDZ-RhoGEF is a downstream effector of TROY signaling,
knockdown of PDZ-RhoGEF would inhibit survival signaling and
increase sensitivity to therapeutic agents. For this experiment, we

Figure 3. PDZ-RhoGEF expression is increased in GBM. (A) IHC analysis of PDZ-RhoGEF expression in non-neoplastic brain and GBM
biopsy samples (upper panel). Samples are representative of 36 matched biopsy samples on a tissue microarray. a, negative, score 0;
b, minimum, score 1; c, moderate, score 2; d, strong, score 3. Neuropathology scoring of the percentage distribution of staining intensity
of PDZ-RhoGEF in GBM patient specimens (lower panel).
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utilized GBM43 which is MGMT promoter unmethylated by
qMS-PCR and thus relatively resistant to TMZ therapy compared to
PDX with MGMT promoter hypermethylation. GBM43 cells expressing
a control nonsilencing shRNA or a shRNA targeting PDZ-RhoGEF
were treated with increasing concentrations of TMZ. Knockdown of
PDZ-RhoGEF in GBM43 cells was verified by immunoblotting analysis
(Figure 2D). Results of cell viability after 72 hours showed that
knockdown of PDZ-RhoGEF significantly reduced GBM43 cell viability
at all doses of TMZ treatment (Figure 2E). These data suggest that
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PDZ-RhoGEF plays an important role in glioma cell invasion and
functions as a downstream effector for the TROY signaling.

PDZ-RhoGEF Expression Is Upregulated in GBM, and
Knockdown of PDZ-RhoGEF Expression Increases Survival of
Orthotopic Xenograft Mice
We have demonstrated that specific Rac1 GEFs (Trio, Ect2, and Vav3)
are upregulated in GBM [27]. To determine the protein expression of

Figure 4. Knockdown of PDZ-RhoGEF expression increases xenograft survival. (A) Kaplan-Meier survival curves of athymic nude mice with
intracranial xenografts of primary GBM10 cells transduced with a control nontargeting shRNA (CTL) or a shRNA-targeting PDZ-RhoGEF (PRG).
Curves show a significant survival benefit for mice with xenografts with silencing PDZ-RhoGEF expression (P = .002). Insert: Western blot of
whole cell lysates of transduced GBM10 cells used for the intracranial xenografts immunoblotted with the indicated antibodies. (B) IHC of
GBM10 tumors transduced with shRNA targeting PDZ-RhoGEF (PRG-shRNA) or a nonsilencing control shRNA (NS ctrl).

Neoplasia Vol. 20, No. 10, 2018

PDZ-RhoGEF Drives TROY-Mediated GBM Cell Invasion

PDZ-RhoGEF in GBM, we examined its expression in GBM tumors
in situ by immunohistochemical (IHC) analysis on a GBM tissue
microarray. IHC analysis of PDZ-RhoGEF expression in 36 clinical
GBM specimens indicated increased expression of PDZ-RhoGEF in
nearly all samples, with 61% of samples exhibiting a moderate staining
score of 2 and 36% a strong score of 3 (on a 0-3 scale) (Figure 3).
To determine the effect of PDZ-RhoGEF expression on glioma tumor
progression in vivo, we examined the effect of silencing PDZ-RhoGEF
expression on the survival of mice with intracranial xenografts established
with GBM10 from a panel of serially in vivo passaged GBM xenografts
established from patient tumors that maintain characteristic morphologic
and molecular properties of the original tumor [21,33]. GBM10 cells,
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which express both TROY and PDZ-RhoGEF (Supplementary Figure 1),
were transduced with shRNA targeting PDZ-RhoGEF or a nontargeting shRNA. Immunoblotting analysis showed that GBM10 cells
transduced with a shRNA-targeting PDZ-RhoGEF (PRG) showed
more than 90% reduction in PDZ-RhoGEF expression compared to
GBM10 cells transduced with a control nontargeting shRNA (CTL)
(Figure 4A). Following intracranial implantation, mice with intracranial
xenografts established with GBM10 cells transduced with the
shRNA-targeting PDZ-RhoGEF exhibited significantly increased
survival compared to mice with xenografts established with GBM10
cells transduced with the control nontargeting shRNA (P = .002).
Immunohistochemical analysis of tumors resected from moribund

Figure 5. Depletion of Rho suppresses TROY and PDZ-RhoGEF-induced glioma cell migration.(A) T98G and T98G/TROY-HA cells were
transfected with a nontargeting control siRNA (siCTRL) or two independent siRNAs targeting PDZ-RhoGEF (siPRG-1, siPRG-2) for
24 hours and infected with FLAG-tagged PRG lentivirus or GFP lentivirus for additional 24 hours. The cells were serum starved overnight
and then seeded on top of a Transwell chamber. The number of migrated cells post 24 hours was quantified using DAPI staining. Data
represent the mean values (+/− SEM) (n = 3, *P b .05; **P b .01; ***P b .001). (B) The lysates of T98G used for migration assay in A
were immunoblotted with indicated antibodies. (C) The lysates of T98G/TROY-HA used for migration assay in A were immunoblotted with
indicated antibodies. (D) T98G and T98G/TROY-HA cells were transfected with a nontargeting control siRNA (siCTRL) or two independent
siRNAs targeting PDZ-RhoGEF (siPRG-1, siPRG-2) for 2 days and then serum starved overnight. Cells were lysed, and the Rho activities in
lysates were measured using GST-Rhotekin-RBD pull-down assay. Immunoblot is a representation of two independent experiments.
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Figure 6. PDZ-RhoGEF (PRG) enhances TROY-induced NF-κB activation. (A) 293 cells expressing a NF-κB-luciferase reporter (293/
NF-κB-luc) were transfected with the indicated plasmids. Twenty-four hours after transfection, cells were serum starved (0.1% BSA) for
16 hours and lysed, and NF-κB-luc reporter expression was measured using a luciferase reporter assay kit. Luciferase activity was
normalized to the vector-transfected cells. The data are depicted as the mean values (+/− SD) (n = 3, *P b .05; **P b .01) (upper panel).
The expression of HA-tagged TROY and Myc-tagged PDZ-RhoGEF in lysates was detected by immunoblotting (bottom panel). (B) 293/
NF-κB-luc reporter cells overexpressing TROY (293/NF-κB-luc/TROY-HA) were transfected with either vector or 0.8 or 1.6 μg Myc-tagged
PDZ-RhoGEF. Twenty-four hours after transfection, cells were serum starved (0.1% BSA) for 16 hours and lysed, and luciferase activity
was measured using luciferase reporter assay kit. Luciferase activity was normalized to the vector-transfected cells. The data are depicted
as the mean values (+/− SD) (n = 3, ***P b .001) (upper panel). Expression levels of PDZ-RhoGEF and TROY were determined by
immunoblot analysis (bottom panel). (C) 293/NF-κB-luc/TROY-HA cells were transfected with either two independent siRNAs targeting
RhoC or RhoA or a control siRNA (siCTRL). Twenty-four hours after transfection, cells were transfected with Myc-tagged PRG plasmid for
an additional 24 hours. Cells were serum starved (0.1% BSA) for 16 hours and lysed, and luciferase activity was measured using a
luciferase reporter assay kit. Luciferase activity was normalized to the control cells. The data are depicted as the mean values (+/− SD)
(n = 3, *P b .05; **P b .01; ***P b .001) (upper panel). Knockdown of RhoC and RhoA expression and overexpression of PDZ-RhoGEF
was verified by immunoblotting (bottom panel). (D) T98G/NF-κB-luc/TROY-HA cells were transfected with either two independent siRNAs
targeting RhoC or RhoA or a control siRNA (siCTRL). Twenty-four hours after transfection, cells were serum starved (0.1% BSA) for
additional 16 hours and lysed, and luciferase activity was measured using a luciferase reporter assay kit. Luciferase activity was
normalized to the control cells. The data are depicted as the mean values (+/− SD) (n = 3, **P b .01; ***P b .001) (upper panel).
Knockdown of RhoC and RhoA expression was verified by immunoblotting (bottom panel).
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animals at the time of sacrifice demonstrated a marked reduction in
staining for PDZ-RhoGEF in tumors between the PDZ-RhoGEF
targeted and control groups (Figure 4B). These data support a role for
PDZ-RhoGEF expression in GBM tumor progression.

Depletion of RhoA and RhoC Inhibits PDZ-RhoGEF and
TROY-Induced Cell Migration
It has been reported that PDZ-RhoGEF is a specific GEF for Rho but
not for Rac1 and Cdc42 [34,35]. Knockdown of PDZ-RhoGEF had no
effect on Rac1 activation in T98G cells (Supplementary Figure 2),
supporting that PDZ-RhoGEF exhanges mainly RhoA and RhoC. To
more closely examine the role of PDZ-RhoGEF, RhoC, and RhoA in
TROY-induced glioma cell migration, we knocked down RhoC and
RhoA expression in T98G cells and T98G cells overexpressing TROY
(T98G/TROY-HA) in the presence of increased PDZ-RhoGEF
expression. T98G and T98G/TROY-HA cells were transfected with
two independent siRNAs targeting RhoC (siRhoC-1, siRhoC-2) or two
independent siRNAs targeting RhoA (siRhoA-1, siRhoA-2) or a
nonsilencing control RNA (siCTRL). After 24 hours, these cells were
infected with FLAG-tagged PDZ-RhoGEF adenovirus or a control
adenovirus expressing GFP for an additional 24 hours. Cells were
serum starved overnight and seeded on top of Transwell chamber. Cell
migration to lower chamber was quantitated after 24 hours. Increased
PDZ-RhoGEF expression enhanced cell migration in both T98G and
T98G/TROY-HA cells (Figure 5A). The increased migration of T98G
and T98G/TROY-HA cells induced by increased PDZ-RhoGEF
expression was significantly inhibited by siRNA-mediated depletion of
RhoC or RhoA (Figure 5A), indicating that RhoC and RhoA may
function as downstream effectors of a TROY/PDZ-RhoGEF signaling
axis. The knockdown of RhoC and RhoA and overexpression of
FLAG-tagged PDZ-RhoGEF in T98G and T98G/TROY-HA cells
were verified by immunoblotting analysis (Figure 5, B and C).
As knockdown of RhoC and RhoA inhibited TROY and
PRG-induced cell migration, we examined the relationship between
Rho activation status and TROY in T98G and T98G/TROY-HA cells.
A Rho activation assay showed that increased TROY expression
enhanced both RhoA and RhoC activation in serum starved cells
(Figure 5D). Moreover, depletion of PDZ-RhoGEF reduced the
TROY-induced RhoA and RhoC activation (Figure 5D). Taken
together, these data suggest that TROY promotes Rho activation
through PDZ-RhoGEF.

PDZ-RhoGEF Enhances TROY-Induced NF-κB Activation
We have previously demonstrated that increased TROY expression
activates the NF-κB pathway in glioblastoma cell lines [14]. We next
examined the effect of association of PDZ-RhoGEF with TROY on
TROY-induced NF-κB activation. 293/NF-κB-luc reporter cells were
transfected with HA-tagged TROY or Myc-tagged PDZ-RhoGEF or
co-transfected with HA-tagged TROY and Myc-tagged PDZ-RhoGEF.
Twenty-four hours after transfection, cells were serum starved for an
additional 16 hours and then subjected to immunoblot analysis and
NF-κB reporter assay. Immunoblotting analysis showed the expression
of TROY and PDZ-RhoGEF in transfected cells (Figure 6A, bottom
panel). Consistent with previous results, increased expression of TROY
stimulated NF-κB activity (Figure 6A, upper panel). In contrast,
increased expression of PDZ-RhoGEF alone did not induce NF-κB
activation above that of control cells. However, coexpression of
PDZ-RhoGEF along with TROY potentiated NF-κB activation above
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that of TROY expression alone (Figure 6A, upper panel). PDZ-RhoGEF
expression enhanced activation of NF-κB in a dose-dependent manner in
293/NF-κB-luc cells stably coexpressing TROY (Figure 6B), corroborating that PDZ-RhoGEF facilitates TROY-induced NF-κB activation.
We also examined whether RhoC or RhoA is involved in TROY- and
PDZ-RhoGEF–induced NF-κB activation. Notably, knockdown of
RhoC or RhoA attenuated the PDZ-RhoGEF–induced activation of
NF-κB in 293/NF-κB-luc/TROY-HA cells (Figure 6C, upper panel).
Immunoblotting analysis showed that siRNA-mediated knockdown of
RhoC or RhoA in 293/NF-κB-luc/TROY-HA cells with two
independent siRNA oligonucleotides was N90% effective (Figure 6C,
bottom panel). We also examined the effects of RhoA or RhoC on
TROY- and PDZ-RhoGEF–induced NF-κB activation in T98G glioma
cells transduced with the NF-κB luciferase reporter and with increased
expression of TROY (T98G/NF-κB-luc/TROY-HA cells). Consistent
with the results observed in 293/NF-κB-luc/TROY-HA cells, knockdown of RhoC or RhoA reduced the TROY-induced NF-κB activation
in the T98G/NF-κB-luc/TROY-HA cells (Figure 6D, upper panel),
which have endogenous PDZ-RhoGEF expression (see Figure 2C).
Immunoblotting analysis showed the RhoC or RhoA in T98G/
NF-κB-luc/TROY-HA cells with two independent siRNAs was N90%
effective (Figure 6D, bottom panel). These data further suggest that
PDZ-RhoGEF functions as a downstream effector of TROY and the
association of PDZ-RhoGEF with TROY potentiates TROY-induced
NF-κB activation, in part, via Rho.
Discussion
Our previous studies have reported that TROY plays an important role
in the regulation of GBM migration and invasion, thereby promoting
GBM survival signaling and therapeutic resistance [13,14]. In this
study, we sought to identify important downstream effector(s) for
TROY signaling in glioblastoma cells. The major findings of this study
are as follows: 1) PDZ-RhoGEF forms a complex with TROY and is
component of a signaling complex that includes Pyk2; 2)
PDZ-RhoGEF expression is upregulated in GBM tumors; 3)
knockdown of PDZ-RhoGEF suppressed TROY-induced glioma cell
migration and decreased therapeutic resistance to TMZ; 4) depletion of
RhoA and RhoC inhibited TROY- and PDZ-RhoGEF–induced cell
migration; 5) depletion of PDZ-RhoGEF suppressed TROY-induced
Rho activation; and 6) PDZ-RhoGEF potentiated TROY-induced
NF-κB activation. Together, these results substantiate the role of
PDZ-RhoGEF as an important effector for TROY signaling and suggest
that targeting PDZ-RhoGEF may represent a novel strategy for GBM
treatment.
This study is the first to identify PDZ-RhoGEF as a component of a
signalsome that includes TROY and the non–receptor tyrosine kinase
Pyk2. Previously, we demonstrated that TROY-induced cell migration
and invasion were dependent upon Pyk2 expression and kinase activity
[13]. Here, we observed via immunoprecipitation that TROY, Pyk2,
and PDZ-RhoGEF could all be found in the same immunoprecipitate.
Moreover, we observed that PDZ-RhoGEF immunoprecipitated with
Pyk2 was phosphorylated but was not phosphorylated when immunoprecipitated with a kinase dead Pyk2 variant. This association appears
to be specific as neither TROY nor Pyk2 co-immunoprecipitated with
the closely related GEF LARG. Further studies are planned to investigate
the temporal assembly of this complex, the domains that mediate the
different interactions, and the functional significance of the phosphorylation of PDZ-RhoGEF by Pyk2.
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It is well appreciated that members of the small family of Rho
GTPases regulate cell motility through their effects on actin dynamics
and cytoskeletal organization [39]. Rho GTPases such as RhoA,
Cdc42, and Rac1 are master regulators of cell migration and
proliferation and are involved in the formation of stress fibers,
induction of lamellipodia, and filopodia protrusion [40]. In addition,
Rho GTPases have been implicated in glioma cell invasion and tumor
progression [20]. Indeed, our earlier study showed that TROY
activates Rac1 signaling in a Pyk2–dependent fashion, leading to
enhanced GBM cell motility [13]. In this study, our data showed that
PDZ-RhoGEF knockdown does not affect Rac1 activation, suggesting
that TROY-mediated Rac1 activation is independent of PDZ-RhoGEF.
In contrast, knockdown of PDZ-RhoGEF inhibited TROY-stimulated
RhoA and RhoC activation in serum-starved glioma cells. Moreover,
knockdown of RhoA or RhoC expression inhibited TROY- and
PDZ-RhoGEF–induced glioma cell migration.
Activity of Rho GTPases is regulated by a large number of Rho
guanine nucleotide exchange factors (RhoGEFs), which activate Rho
GTPases by promoting the exchange of GDP for GTP [17]. To date, it
has been reported that seven Rac1-activating GEFs, including Ect2,
Trio, Vav3, SWAP-70, Dock7, Dock180-ELMO1, and SGEF, enhance
GBM cell migration and invasion [27,41–43]. Six of these GEFs have
been shown to be overexpressed in glioblastoma compared to
non-neoplastic brain (Ect2, Trio, Vav3, SWAP-70, Dock7, and
SGEF) [27,41,43], whereas overexpression of ELMO1 and Dock180
was observed in invasive glioma cells compared to glioma cells in the
tumor core [42]. Here, our observations add PDZ-RhoGEF to this
growing list of GEFs that are involved in GBM cell invasion.
PDZ-RhoGEF, p115RhoGEF, and the leukemia-associated RhoGEF
(LARG) constitute a RhoGEF subfamily (RGS-RhoGEFs) characterized
by the presence of the regulator of G protein signaling (RGS) domain.
Emerging evidence suggests that the role of these RGS-RhoGEFs is varied
in cancer cell invasion and their functions may be tumor specific.
Expression of p115RhoGEF is upregulated in prostate cancer cell lines
(DU145 and PC-3) and invasive prostate tumors [44], whereas LARG
expression is found to be decreased in breast and colon carcinomas,
potentially functioning as a putative tumor suppressor [45]. Overexpression of PDZ-RhoGEF has been noted in several cancers, including breast,
colon, and gallbladder cancers, as well as glioma [31,46–48]. Existing
evidence supports an important role for PDZ-RhoGEF in cancer cell
migration and invasion. For example, PDZ-RhoGEF is required for
CXCR4-promoted breast cancer cell migration and invasion [48].
Immunohistochemistry studies further showed that elevated expression of
PDZ-RhoGEF correlates with an invasive phenotype in human breast
cancer [48]. Here, we demonstrated that PDZ-RhoGEF expression is
upregulated in patient GBM specimens and that depletion of
PDZ-RhoGEF inhibited TROY-induced glioma cell invasion.
Consistent with the observation that migratory/invasive glioma cells
exhibit increased resistance to cytotoxic agents [49,50], the current
results demonstrated that depletion of PDZ-RhoGEF inhibited cellular
invasion and sensitized glioma cells to TMZ-induced apoptosis. This
result is supported by the results of a high-throughput siRNA screen
assay that identified PDZ-RhoGEF as 1 of the 55 survival genes in
T98G glioma cell line, implicating a role of PDZ-RhoGEF in glioma
cell survival signaling [47]. Activation of NF-κB has been shown to
promote cell survival in GBM tumors [14,25,51], and the current
results demonstrate that the association of PDZ-RhoGEF with TROY
further enhanced TROY-induced NF-κB activation. However, we
observed that the knockdown of RhoA or RhoC expression alone does
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not completely inhibit TROY- and PDZ-RhoGEF–induced NF-κB
activation. This partial inhibition of NF-κB induced by TROY and
PDZ-RhoGEF suggests that RhoA and RhoC can compensate for each
other in the activation of NF-κB. In addition, silencing PDZ-RhoGEF
by shRNA significantly prolonged survival in a glioma xenograft model.
Together, these data further support that PDZ-RhoGEF may play an
important role in GBM cell survival.
Immunohistochemical analysis of a glioma tissue microarray
demonstrated that PDZ-RhoGEF expression is significantly increased
in GBM versus non-neoplastic brain. The increased expression of
PDZ-RhoGEF in GBM tumors and its role in GBM cell invasion and
cell survival suggest that PDZ-RhoGEF may represent a novel potential
target for treatment. There is emerging evidence that supports the
feasibility of targeting RhoGEFs as a promising anticancer therapy [52].
For example, it has been reported that selective inhibition of Trio via
targeting the TrioGEFD2 domain by the inhibitor TRIPα inhibits
RhoA activation, thereby inhibiting the neurite retraction phenotype
induced by TrioGEFD2 in PC12 cells [53]. Furthermore,
PDZ-RhoGEF inhibitors are likely to have a wide therapeutic window
since mice deficient in PDZ-RhoGEF do not display any noticeable
phenotype [54].
In summary, the current data establish an important role for
PDZ-RhoGEF as an effector of TROY signaling. The results of this
study show that PDZ-RhoGEF is a component of a signalsome including
TROY, and expression of PDZ-RhoGEF is upregulated in GBM tumors
and potentiates TROY-induced migration and NF-κB activation. In
contrast, depletion of PDZ-RhoGEF suppresses RhoA and RhoC
activation, which results in inhibition of glioma cell invasion and increases
the sensitivity of GBM cells to TMZ treatment. Taken together, these
suggest that PDZ-RhoGEF may represent a potential node of
vulnerability to limit GBM cell invasion and decrease therapeutic
resistance.
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